CSL Behring

Quick facts

Marketed products

• Afstyla® · Hematology
  Afstyla is a recombinant antithrombin III-free factor VIII that replaces deficient clotting factor VIII to restore hemostasis in patients with hemophilia A.
• Blood coagulation Factor VIII and vWF, human
• CE1226 · Other
• Cryoprecipitate · Other
• Filsuvez · Hematology
  Monoclonal antibody that inhibits activated Factor XII (FXIIa), preventing the generation of bradykinin which causes angioedema attacks.
• Haemocomplettan® P · Hematology
  Haemocomplettan® P is a prothrombin complex concentrate (PCC) that replaces deficient vitamin K-dependent clotting factors to restore coagulation capacity.
• Hizentra · Other
• IgPro · Immunology
  IgPro is an intravenous immunoglobulin (IVIG) product that provides passive immunity by supplying pooled human antibodies to help fight infections and modulate immune responses.
• IgPro10
• IgPro20 · Immunology
  IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to patients with primary immunodeficiency.
• Vivaglobin · Other
• Voncento · Other

Phase 3 pipeline

• Alpha-1 antitrypsin (AAT) · Pulmonology / Genetic / Rare Disease
  Alpha-1 antitrypsin (AAT) is a protease inhibitor that replaces deficient endogenous AAT to prevent neutrophil elastase-mediated tissue destruction in the lungs and other organs.
• BE1116 · Hematology
  BE1116 is a recombinant human albumin-von Willebrand factor (VWF) fusion protein that replaces or augments deficient VWF function in von Willebrand disease.
• Beriplex® P/N (Kcentra) · Hematology / Anticoagulation reversal
  Beriplex P/N is a prothrombin complex concentrate that replaces deficient vitamin K-dependent clotting factors to rapidly reverse warfarin anticoagulation.
• CSL312 · Cardiovascular
  CSL312 is an apolipoprotein A-I (apoA-I) mimetic that increases HDL cholesterol and promotes reverse cholesterol transport.
• Factor IX (FIX) · Hematology
  Factor IX is a vitamin K-dependent clotting factor that replaces deficient or dysfunctional Factor IX to restore the intrinsic coagulation pathway and enable normal blood clot formation.
• FXIII Concentrate (Human) · Hematology
  FXIII Concentrate replaces deficient coagulation Factor XIII to restore normal blood clot cross-linking and stabilization.
• Higher-volume C1-esterase inhibitor · Immunology / Rare Disease
  A higher-concentration formulation of C1-esterase inhibitor that suppresses activation of the contact system and complement cascade to prevent angioedema attacks.
• IgPro20 (high dose) · Immunology
  IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to treat primary immunodeficiency.
• IgPro20 (low dose) · Immunology
  IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to patients with primary immunodeficiency.
• Low-volume C1-esterase inhibitor · Immunology / Rare disease
  Low-volume C1-esterase inhibitor (C1-INH) replaces or augments deficient or dysfunctional C1-esterase inhibitor protein to suppress excessive contact system and complement activation.
• rIX-FP · Hematology
  rIX-FP is a recombinant, humanized monoclonal antibody that targets factor VIII to prevent bleeding in patients with hemophilia A.
• rVIII-SingleChain · Hematology
  rVIII-SingleChain is a recombinant single-chain factor VIII that replaces deficient clotting factor VIII to restore hemostasis in hemophilia A patients.

Phase 2 pipeline

• Biostate® [RP] · Immunology
  Biostate is a recombinant human C1 esterase inhibitor used to treat hereditary angioedema.
• Biostate® [SP] · Immunology
  Biostate is a recombinant human C1 esterase inhibitor used to treat hereditary angioedema.
• CSL_112 · Immunology
  CSL_112 is a recombinant human monoclonal antibody that targets the complement system.
• CSL112
• CSL300 · Immunology
  CSL300 is a recombinant human monoclonal antibody that targets the complement system.
• CSL346 · Oncology
  CSL346 is a monoclonal antibody targeting the CD19 protein.
• CSL787
• CSL889
• Factor XIIa antagonist monoclonal antibody
• Infusion without ALD518'

Phase 1 pipeline

• CR002 Liquid API
• CSL040
• Plasma derived FIX [pdFIX]
• rVIIa-FP
• Vamifeport IRF
• Vamifeport PR1
• Vamifeport PR2

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• CSL Behring portfolio CI brief
• CSL Behring pipeline updates RSS

Frequently asked questions about CSL Behring

Related

• Afstyla® · Hematology
• Blood coagulation Factor VIII and vWF, human
• CE1226 · Other
• Cryoprecipitate · Other
• Filsuvez · Hematology
• Sector hub: All tracked pharma companies